West Pharmaceutical Services (WST) Revenue (2009 - 2026)

West Pharmaceutical Services (WST) has 18 years of Revenue data on file, last reported at $844.9 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 21.05% year-over-year to $844.9 million; the trailing twelve-month figure through Mar 2026 stood at $3.2 billion (up 11.23% YoY), and the FY2025 full-year result was $3.1 billion, up 6.25% from the prior year.
• Revenue improved to $844.9 million in Q1 2026, from $805.0 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $844.9 million in Q1 2026 to a low of $686.9 million in Q3 2022.
• A 5-year average of $744.1 million and a median of $746.9 million in 2024 frame the typical range for Revenue.
• Across the five-year window, Revenue decreased 6.86% in 2024 and increased 21.05% in 2026, its largest moves.
• Tracing WST's Revenue over 5 years: stood at $708.7 million in 2022, then advanced by 3.29% to $732.0 million in 2023, then increased by 2.3% to $748.8 million in 2024, then grew by 7.51% to $805.0 million in 2025, then advanced by 4.96% to $844.9 million in 2026.
• Business Quant data shows WST's Revenue at $844.9 million in Q1 2026, $805.0 million in Q4 2025, and $804.6 million in Q3 2025.